Anal Fissure Treatment Market Report 2026

The anal fissure treatment market size has grown strongly in recent years. It will grow from $1.55 billion in 2025 to $1.7 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to increasing prevalence of gastrointestinal disorders, widespread use of conservative treatment approaches, availability of topical nitroglycerin therapies, growing clinical awareness among practitioners, adoption of stool softener regimens.

The anal fissure treatment market size is expected to see strong growth in the next few years. It will grow to $2.41 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to increasing demand for minimally invasive treatments, rising patient preference for home-based care, expansion of specialty colorectal clinics, growing use of combination therapeutic approaches, increasing focus on long-term symptom management. Major trends in the forecast period include increasing use of non-surgical treatment options, rising adoption of topical therapies, growing awareness of early diagnosis and management, expansion of outpatient treatment protocols, enhanced focus on patient comfort and compliance.

The rising incidence of gastrointestinal disorders is expected to drive the growth of the anal fissure treatment market in the coming years. Gastrointestinal disorders, also known as digestive disorders, encompass a range of medical conditions that affect the organs and structures of the gastrointestinal (GI) tract. The increase in gastrointestinal disorders contributes to a corresponding rise in anal fissure cases, boosting demand for effective and targeted treatments within the anal fissure treatment market. For example, in September 2023, the National Library of Medicine, a US-based biomedical library operated by the United States federal government, reported that the overall incidence of Inflammatory Bowel Disease (IBD) in Canada in 2023 was 30 per 100,000, representing 11,000 new diagnoses that year. The incidence is projected to grow by 0.58% annually, reaching 32.1 per 100,000 by 2035. Thus, the increasing prevalence of gastrointestinal disorders is supporting the expansion of the anal fissure treatment market.

Key companies in the anal fissure treatment market are focusing on developing innovative products, such as topical treatments, to reach larger customer bases, boost sales, and increase revenue. Anal fissure topical treatments involve medications or ointments applied directly to the affected area of an anal fissure. For instance, in July 2023, Acrux Limited, an Australia-based pharmaceutical company, announced that the United States Food and Drug Administration (FDA) approved the review of Nitroglycerin Ointment, 0.4%. This ointment is notable for treating moderate to severe pain associated with chronic anal fissures, addressing discomfort caused by tears in the anal lining. The company prioritizes advancing later-stage projects nearing commercialization while simultaneously developing earlier-stage products, ensuring a diverse and well-rounded product pipeline.

In January 2024, Merck KGaA, a Germany-based science and technology company providing anal fissure treatments, partnered with Inspirna Inc. Through this partnership, Merck KGaA expanded its colorectal cancer portfolio via a licensing agreement for the drug ompenaclid (RGX-202). This first-in-class oral inhibitor targets the creatine transport channel SLC6A8 and is currently in Phase II development for advanced RAS-mutated colorectal cancer (mCRC). Inspirna Inc. is a US-based clinical-stage biopharmaceutical company.

Major companies operating in the anal fissure treatment market are Abbott Laboratories, GlaxoSmithKline plc, Bayer AG, Pfizer Inc, Taro Pharmaceutical Industries Ltd, Mallinckrodt Pharmaceuticals Limited, Sanofi S.A., Johnson & Johnson Services Inc, Allergan Inc, Valeant Pharmaceuticals International Inc, Purdue Pharma LP, AstraZeneca plc, Eisai Co. Ltd, Geri-care Pharmaceuticals Corp, Taj Pharmaceuticals Limited, Troikaa Pharmaceuticals Ltd, Eli Lilly and Company, Roche Holding AG, AbbVie Inc, Amgen Inc.

North America was the largest region in the anal fissure treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the anal fissure treatment market report during the forecast period. The regions covered in the anal fissure treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anal fissure treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the anal fissure treatment market by increasing costs of imported pharmaceutical ingredients, topical formulation components, medical consumables, and packaging materials. Healthcare providers and pharmaceutical manufacturers in North America and Europe are most affected due to reliance on imported raw materials and finished dosage forms. These tariffs are contributing to higher treatment costs and supply chain complexity. At the same time, they are encouraging domestic production of topical medications, regional formulation capabilities, and improved sourcing strategies for essential gastrointestinal treatments.

The anal fissure treatment market research report is one of a series of new reports that provides anal fissure treatment market statistics, including anal fissure treatment industry global market size, regional shares, competitors with a anal fissure treatment market share, detailed anal fissure treatment market segments, market trends and opportunities, and any further data you may need to thrive in the anal fissure treatment industry. This anal fissure treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anal fissure treatment involves healing small tears in the thin, moist tissue lining the anus through practices such as sitz baths or the use of stool softeners. These methods help relax the sphincter muscles and promote the healing of the anal fissure.

The main types of anal fissure treatments include topical nitroglycerin, calcium channel blockers, stool softeners, and others. Topical nitroglycerin is an ointment used to treat chronic anal fissures and alleviate moderate to severe discomfort. This medication is part of the nitrate drug family. The primary routes of administration are topical and oral, and these treatments are commonly applied in settings such as clinics, hospitals, and other healthcare facilities.

The anal fissure treatment market includes revenues earned by entities by providing medications such as ointments and therapies for anal fissure. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.